Limits...
Influence of prior influenza vaccination on antibody and B-cell responses.

Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB - PLoS ONE (2008)

Bottom Line: Serum antibody, effector, and memory B-cell responses were greater in TIV recipients than LAIV recipients.Lower levels of baseline HAI titer were associated with a greater fold-increase of HAI titer and ASC number after vaccination, which also differed by type of vaccine.In particular, prior year TIV vaccination is associated with sustained higher HAI titer one year later but lower antibody response to new LAIV or TIV vaccination, and a lower effector B-cell response to new TIV but not LAIV vaccination.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.

ABSTRACT
Currently two vaccines, trivalent inactivated influenza vaccine (TIV) and live attenuated influenza vaccine (LAIV), are licensed in the USA. Despite previous studies on immune responses induced by these two vaccines, a comparative study of the influence of prior influenza vaccination on serum antibody and B-cell responses to new LAIV or TIV vaccination has not been reported. During the 2005/6 influenza season, we quantified the serum antibody and B-cell responses to LAIV or TIV in adults with differing influenza vaccination histories in the prior year: LAIV, TIV, or neither. Blood samples were collected on days 0, 7-9 and 21-35 after immunization and used for serum HAI assay and B-cell assays. Total and influenza-specific circulating IgG and IgA antibody secreting cells (ASC) in PBMC were detected by direct ELISPOT assay. Memory B cells were also tested by ELISPOT after polyclonal stimulation of PBMC in vitro. Serum antibody, effector, and memory B-cell responses were greater in TIV recipients than LAIV recipients. Prior year TIV recipients had significantly higher baseline HAI titers, but lower HAI response after vaccination with either TIV or LAIV, and lower IgA ASC response after vaccination with TIV than prior year LAIV or no vaccination recipients. Lower levels of baseline HAI titer were associated with a greater fold-increase of HAI titer and ASC number after vaccination, which also differed by type of vaccine. Our findings suggest that the type of vaccine received in the prior year affects the serum antibody and the B-cell responses to subsequent vaccination. In particular, prior year TIV vaccination is associated with sustained higher HAI titer one year later but lower antibody response to new LAIV or TIV vaccination, and a lower effector B-cell response to new TIV but not LAIV vaccination.

Show MeSH

Related in: MedlinePlus

The percentage of circulating influenza-specific memory B cells before and after LAIV or TIV vaccination.Percentages of influenza-specific memory IgG B-cells and IgA B-cells before (day 0) and 30 day (21–35 days in 2005 study, 27–47 days in 2004 study) after LAIV or TIV vaccination were measured. A: Comparisons of the percentages of influenza-specific memory IgA and IgG B-cells on day 0 and day 30 after LAIV ('05-LAIV) or TIV ('05-TIV) vaccination. B: Comparisons of memory IgG B-cell levels before vaccination in sub-groups based on the influenza vaccine received in the prior year: TIV ('03-T, '04-T), LAIV ('03-L), or no vaccination ('04-N). C: Comparisons of memory IgG B-cell levels one month after vaccination with '05-LAIV or '05-TIV between sub-groups '04-N and '04-T. The horizontal bars indicate the mean values. *, P<.05, **, P<.01, unpaired t-test.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2500171&req=5

pone-0002975-g004: The percentage of circulating influenza-specific memory B cells before and after LAIV or TIV vaccination.Percentages of influenza-specific memory IgG B-cells and IgA B-cells before (day 0) and 30 day (21–35 days in 2005 study, 27–47 days in 2004 study) after LAIV or TIV vaccination were measured. A: Comparisons of the percentages of influenza-specific memory IgA and IgG B-cells on day 0 and day 30 after LAIV ('05-LAIV) or TIV ('05-TIV) vaccination. B: Comparisons of memory IgG B-cell levels before vaccination in sub-groups based on the influenza vaccine received in the prior year: TIV ('03-T, '04-T), LAIV ('03-L), or no vaccination ('04-N). C: Comparisons of memory IgG B-cell levels one month after vaccination with '05-LAIV or '05-TIV between sub-groups '04-N and '04-T. The horizontal bars indicate the mean values. *, P<.05, **, P<.01, unpaired t-test.

Mentions: Previously we observed that most adults had preexisting influenza-specific memory IgG B cells in their circulation before vaccination [5]. In addition, one month after TIV but not LAIV immunization, the percentage of influenza-specific memory IgG B cells in circulation increased significantly, with a higher percentage of memory IgA and IgG B cells induced by TIV compared to LAIV [5]. In the current study we again studied the memory B-cell levels before and one month after ′05-TIV and ′05-LAIV vaccination in adult subjects (Figure 4). Of the 61 adults, we analyzed the memory B-cell response in the 37 adults who were not involved in the 2004–2005 study. Of these 37 subjects, 8 had received TIV, one had received LAIV, and 28 had not received either vaccine in the prior year. At baseline (day 0), no significant difference was detected in the average percentages of circulating influenza-specific memory IgA and IgG B cells between the ′05-LAIV and ′05-TIV groups (P = .682 and .71, respectively, unpaired t-test) (Figure 4A). One month after immunization, significant increases in the percentage of influenza-specific memory IgG B cells were observed in both ′05-LAIV and ′05-TIV recipients, with the increase in ′05-TIV recipients significantly greater than that in the ′05-LAIV recipients (2.50±0.44, mean±standard error vs. 0.73±0.23, P = .0019, unpaired t-test with Welch's correction). The mean percentage of memory IgA B cells also significantly increased in ′05-TIV recipients (P = .039, unpaired t-test with Welch's correction), while no significant increase was detected in the new ′05-LAIV recipients.


Influence of prior influenza vaccination on antibody and B-cell responses.

Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB - PLoS ONE (2008)

The percentage of circulating influenza-specific memory B cells before and after LAIV or TIV vaccination.Percentages of influenza-specific memory IgG B-cells and IgA B-cells before (day 0) and 30 day (21–35 days in 2005 study, 27–47 days in 2004 study) after LAIV or TIV vaccination were measured. A: Comparisons of the percentages of influenza-specific memory IgA and IgG B-cells on day 0 and day 30 after LAIV ('05-LAIV) or TIV ('05-TIV) vaccination. B: Comparisons of memory IgG B-cell levels before vaccination in sub-groups based on the influenza vaccine received in the prior year: TIV ('03-T, '04-T), LAIV ('03-L), or no vaccination ('04-N). C: Comparisons of memory IgG B-cell levels one month after vaccination with '05-LAIV or '05-TIV between sub-groups '04-N and '04-T. The horizontal bars indicate the mean values. *, P<.05, **, P<.01, unpaired t-test.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2500171&req=5

pone-0002975-g004: The percentage of circulating influenza-specific memory B cells before and after LAIV or TIV vaccination.Percentages of influenza-specific memory IgG B-cells and IgA B-cells before (day 0) and 30 day (21–35 days in 2005 study, 27–47 days in 2004 study) after LAIV or TIV vaccination were measured. A: Comparisons of the percentages of influenza-specific memory IgA and IgG B-cells on day 0 and day 30 after LAIV ('05-LAIV) or TIV ('05-TIV) vaccination. B: Comparisons of memory IgG B-cell levels before vaccination in sub-groups based on the influenza vaccine received in the prior year: TIV ('03-T, '04-T), LAIV ('03-L), or no vaccination ('04-N). C: Comparisons of memory IgG B-cell levels one month after vaccination with '05-LAIV or '05-TIV between sub-groups '04-N and '04-T. The horizontal bars indicate the mean values. *, P<.05, **, P<.01, unpaired t-test.
Mentions: Previously we observed that most adults had preexisting influenza-specific memory IgG B cells in their circulation before vaccination [5]. In addition, one month after TIV but not LAIV immunization, the percentage of influenza-specific memory IgG B cells in circulation increased significantly, with a higher percentage of memory IgA and IgG B cells induced by TIV compared to LAIV [5]. In the current study we again studied the memory B-cell levels before and one month after ′05-TIV and ′05-LAIV vaccination in adult subjects (Figure 4). Of the 61 adults, we analyzed the memory B-cell response in the 37 adults who were not involved in the 2004–2005 study. Of these 37 subjects, 8 had received TIV, one had received LAIV, and 28 had not received either vaccine in the prior year. At baseline (day 0), no significant difference was detected in the average percentages of circulating influenza-specific memory IgA and IgG B cells between the ′05-LAIV and ′05-TIV groups (P = .682 and .71, respectively, unpaired t-test) (Figure 4A). One month after immunization, significant increases in the percentage of influenza-specific memory IgG B cells were observed in both ′05-LAIV and ′05-TIV recipients, with the increase in ′05-TIV recipients significantly greater than that in the ′05-LAIV recipients (2.50±0.44, mean±standard error vs. 0.73±0.23, P = .0019, unpaired t-test with Welch's correction). The mean percentage of memory IgA B cells also significantly increased in ′05-TIV recipients (P = .039, unpaired t-test with Welch's correction), while no significant increase was detected in the new ′05-LAIV recipients.

Bottom Line: Serum antibody, effector, and memory B-cell responses were greater in TIV recipients than LAIV recipients.Lower levels of baseline HAI titer were associated with a greater fold-increase of HAI titer and ASC number after vaccination, which also differed by type of vaccine.In particular, prior year TIV vaccination is associated with sustained higher HAI titer one year later but lower antibody response to new LAIV or TIV vaccination, and a lower effector B-cell response to new TIV but not LAIV vaccination.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.

ABSTRACT
Currently two vaccines, trivalent inactivated influenza vaccine (TIV) and live attenuated influenza vaccine (LAIV), are licensed in the USA. Despite previous studies on immune responses induced by these two vaccines, a comparative study of the influence of prior influenza vaccination on serum antibody and B-cell responses to new LAIV or TIV vaccination has not been reported. During the 2005/6 influenza season, we quantified the serum antibody and B-cell responses to LAIV or TIV in adults with differing influenza vaccination histories in the prior year: LAIV, TIV, or neither. Blood samples were collected on days 0, 7-9 and 21-35 after immunization and used for serum HAI assay and B-cell assays. Total and influenza-specific circulating IgG and IgA antibody secreting cells (ASC) in PBMC were detected by direct ELISPOT assay. Memory B cells were also tested by ELISPOT after polyclonal stimulation of PBMC in vitro. Serum antibody, effector, and memory B-cell responses were greater in TIV recipients than LAIV recipients. Prior year TIV recipients had significantly higher baseline HAI titers, but lower HAI response after vaccination with either TIV or LAIV, and lower IgA ASC response after vaccination with TIV than prior year LAIV or no vaccination recipients. Lower levels of baseline HAI titer were associated with a greater fold-increase of HAI titer and ASC number after vaccination, which also differed by type of vaccine. Our findings suggest that the type of vaccine received in the prior year affects the serum antibody and the B-cell responses to subsequent vaccination. In particular, prior year TIV vaccination is associated with sustained higher HAI titer one year later but lower antibody response to new LAIV or TIV vaccination, and a lower effector B-cell response to new TIV but not LAIV vaccination.

Show MeSH
Related in: MedlinePlus